US2016279357A1PendingUtilityA1

Nasal devices

50
Assignee: OPTINOSE ASPriority: Jun 12, 2001Filed: Nov 2, 2015Published: Sep 29, 2016
Est. expiryJun 12, 2021(expired)· nominal 20-yr term from priority
Inventors:Per Gisle Djupesland
A61P 37/08A61P 27/16A61M 2210/0618A61M 2210/0625A61M 15/08A61M 15/0091A61M 15/0098A61M 2202/064A61P 29/00A61M 15/0021A61M 11/00
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A nasal delivery device for and a method of delivering a substance, in particular one of a liquid, as a suspension or solution, or a powder containing a medicament, especially systemic or topical pharmaceuticals, or a vaccine to the nasal airway of a subject.

Claims

exact text as granted — not AI-modified
1 - 403 . (canceled) 
     
     
         404 . A nasal delivery device for delivering a substance to a nasal airway of a subject, comprising:
 a nosepiece unit configured to fit in a nostril of the subject, the nosepiece unit including a nozzle through which the substance is delivered to the nasal airway of the subject;   a mouthpiece unit configured to fit in a mouth of the subject and receive a flow of exhalation breath from the subject, whereby exhalation by the subject causes closure of a oropharyngeal velum of the subject;   a flow channel fluidly connecting the nosepiece unit and the mouthpiece unit, whereby exhalation breath flows from the mouthpiece unit through the fluid channel and out of the nosepiece unit;   at least one cuff member, which includes at least one lobe, configured to extend into a region of the nasal cavity of the subject and engage an inner wall of the nasal cavity of the subject when fitted in the nasal cavity of the subject; and   a delivery unit for delivering the substance through the nozzle of the nosepiece unit.   
     
     
         405 . The delivery device of  claim 404 , wherein the substance is a powder. 
     
     
         406 . The delivery device of  claim 405 , wherein the powder is a pharmaceutical. 
     
     
         407 . The delivery device of  claim 406 , wherein the powder is an anti-migraine composition. 
     
     
         408 . The delivery device of  claim 404 , wherein the substance is delivered to a site within the nasal airway of the subject. 
     
     
         409 . The delivery device of  claim 408 , wherein the site includes at least a part of the inferior meatus. 
     
     
         410 . The delivery device of  claim 408 , wherein the site includes at least a part of the middle meatus. 
     
     
         411 . The delivery device of  claim 408 , wherein the site includes an inferior part of the middle meatus. 
     
     
         412 . The delivery device of  claim 408 , wherein the site includes at least a part of the superior meatus. 
     
     
         413 . The delivery device of  claim 408 , wherein the site includes at least a part of the inferior nasal concha. 
     
     
         414 . The delivery device of  claim 408 , wherein the site includes at least a part of the middle nasal concha. 
     
     
         415 . The delivery device of  claim 408 , wherein the site includes at least a part of the superior nasal concha. 
     
     
         416 . The delivery device of  claim 408 , wherein the site includes at least a part of the olfactory region. 
     
     
         417 . The delivery device of  claim 408 , wherein the site includes at least a sinus ostia. 
     
     
         418 . The delivery device of  claim 408 , wherein the site includes at a least sinus infundibulum. 
     
     
         419 . The delivery device of  claim 408 , wherein the site includes at least a part of the epipharynx. 
     
     
         420 . The delivery device of  claim 408 , wherein the site includes at least adenoids. 
     
     
         421 . The delivery device of  claim 408 , wherein the site includes at least tubal ostia. 
     
     
         422 . The delivery device of  claim 404 , wherein more than half of the particles in a particle size distribution of the substance are in the range of about 1 μm to about 80 μm. 
     
     
         423 . The delivery device of  claim 404 , wherein more than half of the particles in a particle size distribution of the substance are in the range of about 1 μm to about 50 μm. 
     
     
         424 . The delivery device of  claim 404 , wherein more than half of the particles in a particle size distribution of the substance are in the range of about 1 μm to about 30 μm. 
     
     
         425 . The delivery device of  claim 404 , wherein more than half of the particles in a particle size distribution of the substance are in the range of about 10 μm to about 30 μm. 
     
     
         426 . The delivery device of  claim 404 , wherein more than half of the particles in a particle size distribution of the substance are in the range of about 10 μm to about 20 μm. 
     
     
         427 . The delivery device of  claim 404 , wherein more than half of the particles in a particle size distribution of the substance are in the range of about 15 μm to about 30 μm. 
     
     
         428 . The delivery device of  claim 404 , wherein the nosepiece is a replaceable unit. 
     
     
         429 . The delivery device of  claim 404 , wherein the at least one cuff member includes a plurality of lobes, the at least one cuff member configured to at least partially block the nasal cavity of the subject. 
     
     
         430 . The delivery device of  claim 404 , wherein the delivery unit is configured to deliver the substance to the nozzle in response to the flow of exhalation breath. 
     
     
         431 . A nasal delivery device for delivering a substance to a nasal airway of a subject, comprising:
 a nosepiece unit configured to fit in a nostril of the subject, the nosepiece unit including a nozzle through which the substance is delivered to the nasal airway of the subject;   a mouthpiece unit configured to fit in a mouth of the subject and receive a flow of exhalation breath from the subject, whereby exhalation by the subject causes closure of a oropharyngeal velum of the subject;   a flow channel fluidly connecting the nosepiece unit and the mouthpiece unit, whereby exhalation breath flows from the mouthpiece unit through the fluid channel and out of the nosepiece unit; and   a delivery unit for delivering the substance through the nozzle of the nosepiece unit;   wherein the substance is a powder, a pharmaceutical, and an anti-migraine composition.   
     
     
         432 . The delivery device of  claim 431 , wherein the substance is delivered to a site within the nasal airway of the subject. 
     
     
         433 . The delivery device of  claim 432 , wherein the site includes at least a part of the inferior meatus. 
     
     
         434 . The delivery device of  claim 432 , wherein the site includes at least a part of the middle meatus. 
     
     
         435 . The delivery device of  claim 432 , wherein the site includes an inferior part of the middle meatus. 
     
     
         436 . The delivery device of  claim 432 , wherein the site includes at least a part of the superior meatus. 
     
     
         437 . The delivery device of  claim 432 , wherein the site includes at least a part of the inferior nasal concha. 
     
     
         438 . The delivery device of  claim 432 , wherein the site includes at least a part of the middle nasal concha. 
     
     
         439 . The delivery device of  claim 432 , wherein the site includes at least a part of the superior nasal concha. 
     
     
         440 . The delivery device of  claim 432 , wherein the site includes at least a part of the olfactory region. 
     
     
         441 . The delivery device of  claim 432 , wherein the site includes at least a sinus ostia. 
     
     
         442 . The delivery device of  claim 432 , wherein the site includes at a least sinus infundibulum. 
     
     
         443 . The delivery device of  claim 432 , wherein the site includes at least a part of the epipharynx. 
     
     
         444 . The delivery device of  claim 432 , wherein the site includes at least adenoids. 
     
     
         445 . The delivery device of  claim 432 , wherein the site includes at least tubal ostia. 
     
     
         446 . The delivery device of  claim 431 , wherein more than half of the particles in a particle size distribution of the substance are in the range of about 1 μm to about 80 μm. 
     
     
         447 . The delivery device of  claim 431 , wherein more than half of the particles in a particle size distribution of the substance are in the range of about 1 μm to about 50 μm. 
     
     
         448 . The delivery device of  claim 431 , wherein more than half of the particles in a particle size distribution of the substance are in the range of about 1 μm to about 30 μm. 
     
     
         449 . The delivery device of  claim 431 , wherein more than half of the particles in a particle size distribution of the substance are in the range of about 10 μm to about 30 μm. 
     
     
         450 . The delivery device of  claim 431 , wherein more than half of the particles in a particle size distribution of the substance are in the range of about 10 μm to about 20 μm. 
     
     
         451 . The delivery device of  claim 431 , wherein more than half of the particles in a particle size distribution of the substance are in the range of about 15 μm to about 30 μm. 
     
     
         452 . The delivery device of  claim 431 , further comprising at least one cuff member, wherein the at least one cuff member includes a plurality of lobes, the at least one cuff member configured to at least partially block the nasal cavity of the subject. 
     
     
         453 . The delivery device of  claim 431 , wherein the delivery unit is configured to deliver the substance to the nozzle in response to the flow of exhalation breath.

Join the waitlist — get patent alerts

Track US2016279357A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.